Retinal vascular regeneration.
We discuss the potential use of stem cells for therapeutic angiogenesis in the treatment of retinal diseases. We demonstrate that the clinical utility of these EPC may be not limited in the treatment of ischemic retinal diseases but may also have application for the treatment of retinal degenerative disorders and for a form of cell-based gene therapy. One of the greatest potential benefits of bone marrow derived EPC therapy is the possible use of autologous grafts. Nonetheless, potential toxicities and unregulated cell growth will need to be carefully evaluated before this approach is brought to the clinics.
Otani
Atsushi
A
Kyoto University, Japan. otan@kuhp.kyoto-u.ac.jp
Friedlander
Martin
M
D000818:Animals; D004730:Endothelium, Vascular / Q000166:cytology*; D006801:Humans; D018919:Neovascularization, Physiologic / Q000502:physiology*; D012038:Regeneration / Q000502:physiology*; D012164:Retinal Diseases / Q000601:surgery*; D012171:Retinal Vessels / Q000502:physiology*; D033581:Stem Cell Transplantation; D013234:Stem Cells